Eximia Research has integrated Tidewater Clinical Research into its national network of clinical trial sites—uniting Tidewater’s expertise in Women’s Health and Ophthalmology with Eximia’s clinical trial experience and resources.

Since its inception in 1994, Tidewater has led advancements in Women’s Health through clinical trials in the Hampton Roads/Eastern Virginia region, boasting a substantial patient database and a strong network of investigators. The addition of Tidewater’s 97,000 patients brings Eximia’s total patient volume up to nearly one million patients nationwide.

With this acquisition, under the leadership of CEO Dr. Ella Grach, Eximia is set to broaden its impact on patient health in the mid-Atlantic US, building upon the existing presence nationwide. Together, the sites will advance medical research in specialized therapeutic areas.

“We are excited to welcome Tidewater Clinical Research to the Eximia network,” says Grach. “Their expertise in Women’s Health and Ophthalmology complements our mission to drive innovation and improve patient outcomes. This acquisition enhances our ability to serve diverse populations and support groundbreaking clinical research nationwide.”

“Tidewater Clinical Research is proud to announce our integration into the Eximia Research Network, marking a significant step forward in enhancing clinical research accessibility and quality of care for diverse patient populations,” says Kelly Fleming, co-founder of Tidewater.

April Rusch, co-founder, adds, “Under the Eximia umbrella, Tidewater is poised to broaden its impact on patient health and contribute to the advancement of medical research in ever-expanding medical subspecialty areas, reinforcing its commitment to the community and the pharmaceutical industry at large.”